Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

This is a Phase II, single arm study. All subjects will receive Zanzalintinib 60 mg orally once daily until progression per RECIST 1.1 or intolerable toxicities or patient/investigator decision to discontinue study therapy. Radiology imaging will be performed every 8 weeks for 3 timepoints then every 12 weeks thereafter. A window of ± 7 days may be applied to all study visits to accommodate observed holidays, inclement weather, scheduling conflicts etc.

NCT Number	NCT07185945
Lead Sponsor	Guru Sonpavde Collaborators: Exelixis, Advent Health
Conditions	Advanced Urothelial Carcinoma
Enrollment	44 participants
Start Date	2026-06
Primary Completion	2027-06 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-18